Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Diabetes (Type 2) — Weekly Report — September 28, 2026

Home/Health Insights/Diabetes (Type 2) — September 28 – October 5, 2026
Vol. 7 · No. 47
DoctiPlus Care · Weekly Brief on Diabetes (Type 2)
Updated Monday · November 16, 2026
Diabetes (Type 2) · September 28 – October 5, 2026

Diabetes (Type 2)
Weekly Report

This week's data 31 new clinical trials registered across 10 countries, with 1,951 trials actively recruiting patients worldwide.
Week of September 28 – October 5, 2026
  • 31 new clinical trials registered across 10 countries.
  • 1,951 trials actively recruiting patients worldwide.
  • Notable trial: Evaluation of the Effectiveness of Implementing a Screening Strategy for the Diagnosis of Prediabetes and Type 2 Diab... (45000 patients).
  • 2,370 new research papers published.
  • Top cited: "Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes acro..." (Nature Communications, 29 citations).
  • Drug safety: Most reported effect across tracked medications (metformin, semaglutide, sitagliptin, empagliflozin, insulin glargine) was Off Label Use.
  • No active drug recalls for tracked medications this week.

The week in numbers

Figures · September 28 – October 5, 2026
New Trials This Week
31.
registered Sep 28–Oct 5
Recruiting Now
1,951
active trials seeking patients
Countries
10
with active trials this week
Papers Published
2,370
new studies this week
Phase 3 Trials
3
late-stage trials this week
Fig. 01

Trials by country

Count · September 28 – October 5, 2026
United States
9
Not specified
8
Canada
4
Poland
4
Turkey (Türkiye)
3
China
3
Egypt
2
France
2
Brazil
2
Colombia
2
0 3 6 9
total
Fig. 02

Trials by phase

Distribution · September 28 – October 5, 2026

New clinical trials registered this week for Diabetes (Type 2). Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

31 trials registered for Diabetes (Type 2). Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 Corticosteroid for Diabetic Macular Edema (DME) Study Diabetes (Type 2) · Vanderbilt University Medical Center (NCT07843849) Phase 4 Recruiting 20 United States
02 a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers Diabetes (Type 2) · Applied Biologics, LLC (NCT07852338) Phase 3 Recruiting 253 United States
03 Gastrointestinal Symptoms in Children With Type 1 Diabetes Diabetes (Type 2) · Assiut University (NCT07845175) Other Not Yet Recruiting 254 N/A
04 Clinical Predictors and Therapeutic Gaps in CKM Syndrome Among Adults With Type 2 Diabetes Diabetes (Type 2) · Assiut University (NCT07854990) Other Not Yet Recruiting 231 Egypt
05 Impact of Dietary Intervention Within an Interprofessional Cooperative Protocol for Prandial Insulin Dose Adjustment in People Living With Type 1 Diabetes Diabetes (Type 2) · Assistance Publique - Hôpitaux de Paris (NCT07846852) Other Not Yet Recruiting 163 France
06 Educational Intervention for Self-Care in Patients With Coronary Heart Disease and Type 2 Diabetes Diabetes (Type 2) · Suleyman Demirel University (NCT07852715) Other Completed 70 Turkey (Türkiye)
07 Functional Mobility and Resistance Exercise for Postmenopausal Females With Type 1 Diabetes Diabetes (Type 2) · Institut de Recherches Cliniques de Montreal (NCT07851662) Other Not Yet Recruiting 63 Canada
08 The LifeMeds Cohort Diabetes (Type 2) · Tilburg University (NCT07846800) Other Not Yet Recruiting 2,000 N/A
09 Effects of Hourly Stair-Climbing Exercise Snacks on Metabolic and Vascular Health in Adults With Prediabetes Diabetes (Type 2) · St. Louis University (NCT07847684) Other Recruiting 20 United States
10 Platelet Indices and Blood Groups in Type 2 Diabetes Vascular Complications Diabetes (Type 2) · Assiut University (NCT07847099) Other Not Yet Recruiting 100 N/A
11 A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication Diabetes (Type 2) · Novo Nordisk A/S (NCT07855133) Phase 1 Not Yet Recruiting 60 United States
12 Pivotal Trial for an Automated AI-based System for Detection of Diabetic Retinopathy Diabetes (Type 2) · Digital Diagnostics, Inc. (NCT07844317) Other Recruiting 800 United States
13 A Study of HRS-4729 Injection in Participants With Type 2 Diabetes Diabetes (Type 2) · Fujian Shengdi Pharmaceutical Co., Ltd. (NCT07843862) Phase 2 Not Yet Recruiting 240 China
14 Nurse-Led Self-Management and Breathing Intervention in Type 2 Diabetes Diabetes (Type 2) · Aziza Ibrahim Mohamed (NCT07847177) Other Completed 80 Egypt
15 Precision Nutrition for Obesity and Prediabetes Prevention in Under-supported Communities Diabetes (Type 2) · Prairie View A&M University (NCT07850531) Other Not Yet Recruiting 100 United States
16 SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight Diabetes (Type 2) · Boehringer Ingelheim (NCT07855900) Phase 3 Not Yet Recruiting 350 United States
17 A Study of Fresh Produce and AI-Enabled Nutrition Support in Adults With Diabetes in Rural Appalachia Diabetes (Type 2) · The University of Tennessee, Knoxville (NCT07853703) Other Active Not Recruiting 40 United States
18 The Effectiveness of an Occupation-Based Lifestyle Program in Individuals With Type 2 Diabetes Diabetes (Type 2) · Ankara Medipol University (NCT07847294) Other Recruiting 42 Turkey (Türkiye)
19 A Cluster-Randomized Controlled Trial Diabetes (Type 2) · Second Affiliated Hospital of Nanchang University (NCT07845448) Other Not Yet Recruiting 14,400 N/A
20 JAK1 Inhibitor Ivarmacitinib for Improving Pancreatic Islet Function in T1D Diabetes (Type 2) · Huijie Zhang (NCT07845955) Phase 2 Not Yet Recruiting 132 China
21 The Effect of Different Auditory Types on Visual Evoked Potentials (VEP) Diabetes (Type 2) · King Saud University (NCT07850245) Other Completed 68 Saudi Arabia
22 Pancreatin Added to Standard Antihyperglycemic Therapy in Patients With Type 2 Diabetes Diabetes (Type 2) · Silesian Centre for Heart Diseases (NCT07852988) Phase 4 Recruiting 100 Poland
23 Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors Diabetes (Type 2) · McGill University Health Centre/Research Institute of the McGill University Health Centre (NCT07848204) Phase 1 Completed 24 Canada
24 Lumbopelvic Stability in Gestational Diabetes Mellitus Diabetes (Type 2) · Riphah International University (NCT07851753) Other Recruiting 170 Pakistan
25 Soluble TREM-1 in Diabetes-Associated Cardiovascular Complications Diabetes (Type 2) · Assiut University (NCT07847112) Other Not Yet Recruiting 85 N/A
26 Effect of Otago vs. Sensorimotor Training on Balance and Fall Risk in People With Diabetes Diabetes (Type 2) · Cairo University (NCT07854496) Other Not Yet Recruiting 40 N/A
27 Multimodal Risk Factor Graph Mapping, Metabolic Subtyping, and Digital Intelligent Chronic Disease Management for Prediabetes: An Integrated Cohort and Case-Control Clinical Study Diabetes (Type 2) · Nanjing Medical University (NCT07854002) Other Not Yet Recruiting 30,000 N/A
28 Evaluation of the Effectiveness of Implementing a Screening Strategy for the Diagnosis of Prediabetes and Type 2 Diabetes Mellitus in Primary Health Care in a Brazilian Municipality Diabetes (Type 2) · epHealth (NCT07846319) Other Not Yet Recruiting 45,000 Brazil
29 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes Diabetes (Type 2) · Hoffmann-La Roche (NCT07843485) Phase 3 Not Yet Recruiting 600 N/A
30 Probiotics in Obese Patients Treated With GLP-1 Receptor Agonists Diabetes (Type 2) · Nordic Biotic Sp. z o.o. (NCT07847593) Other Completed 102 Poland
31 Adaptation, Implementation, and Validation of an Innovative eHealth System for the Self-management, Monitoring, and Specialized Remote Medical Care of Patients With Diabetes in the Municipalities of Palermo (Huila) and Suárez (Cauca). Diabetes (Type 2) · Universidad Antonio Nariño (NCT07849725) Other Not Yet Recruiting 200 Colombia
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Diabetes (Type 2). These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
metformin Diarrhoea 2,240
semaglutide Nausea 2,963
sitagliptin Nausea 330
empagliflozin Nausea 823
insulin glargine Off Label Use 4,775

Recalls & safety notices

§ 05 · 0 items this week

FDA drug recall notices for medications related to Diabetes (Type 2). If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

No active drug recalls for tracked medications this period.

§ 06

Published research

2,370 papers

Recently published peer-reviewed studies related to Diabetes (Type 2), sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Multi-metal co-exposure and type 2 diabetes: integrating biomonitoring evidence, inflammatory mechanisms, and a framework for future risk stratification. Mishra RK et al. 10.1007/s10653-026-03518-9
View abstract

Diabetes Mellitus Type 2 prevalence is still increasing around the world, and there is growing evidence of the role of environmental co-exposures to heavy metals-cadmium, lead, arsenic, mercury, and chromium-in glycaemia impairment. Contrarily to studies on single metal toxicology, real-life situations consist in exposure to mixtures of heavy metals through environmental, occupational and dietary pathways, especially in places like the Indo-Gangetic plain of India, characterized by the presence of geological arsenic pollution in association with metals exposure. This paper provides a narrative review on the current state of art in the domain of three key issues connected to risk stratification in Type 2 Diabetes Mellitus: methods for biomonitoring metals, inflammatory and molecular pathways involved in diabetes onset and progression related to metal exposures and statistical approaches for modeling joint effects of mixtures. Firstly, discuss on the biomonitoring methods, with particular emphasis to blood, urine and hair and nail as classical matrices and new emerging matrices (saliva, buccal cells). The analytical technique (AAS vs ICP-MS) is considered as well. It will focus on the heterogeneity between different methodologies, including matrix-specific exposure window and inter-laboratory variability. Regarding mechanistic aspects, there is an agreement in scientific literature on several molecular pathways involved in glycaemia alterations, including oxidative stress, NF-κB inflammation pathway, mitochondria dysfunction, epigenetics alteration and insulin signaling impairment, with possible synergistic rather than additive action of heavy metals in the impairment of beta-cell function and insulin resistance. Finally, it discusses some recent advances in quantifying joint metal effects on diabetes through specific statistics as WQS regression and Bayesian Kernel Machine regression (BKMR) and quantile g-computation. Even though important methodological advances have been made, a translational gap remains: no validated procedure currently exists that integrates exposure metrics, inflammatory biomarkers and clinical variables for individual risk stratification. We therefore outline a research-stage framework that could guide future development of such tools.

Environmental geochemistry and health 2026 Oct 4 PubMed
02 Prior Use of GLP-1 Receptor Agonists versus SGLT2 Inhibitors and Clinical Outcomes After Sepsis in Patients with Type 2 Diabetes: A Propensity Score-Matched Cohort Study. Liu HH et al. 10.2147/DDDT.S642220
View abstract

BACKGROUND: Whether pre-existing glucose-lowering therapy influences outcomes after sepsis remains uncertain. We compared clinical outcomes among patients with type 2 diabetes (T2D) who developed sepsis according to prior GLP-1 receptor agonists (GLP-1RAs) or SGLT2 inhibitors (SGLT2is) use. METHODS: We conducted a retrospective cohort study using the TriNetX US Collaborative Network. Adults with T2D who developed sepsis had received a GLP-1RA or an SGLT2i within 3 months before sepsis were identified. After 1:1 propensity score matching, 11,969 patients were included in each group. The primary outcome was 90-day all-cause mortality. Secondary outcomes included major adverse cardiovascular event (MACE), major adverse kidney event (MAKE), intensive care unit (ICU) admission, major adverse cardiac and cerebrovascular event (MACCE), septic shock, and acute respiratory failure. RESULTS: Compared with prior SGLT2i use, prior GLP-1RA use was associated with lower 90-day all-cause mortality (incidence rate, 48.6 vs 60.6 per 100 person-years; HR, 0.81; 95% CI, 0.75-0.88; E-value: 1.6) and lower risks of MACE (HR, 0.77; 0.65-0.91; E-value, 1.7), myocardial infarction (HR, 0.82; 0.67-0.99; E-value, 1.7), ICU admission (HR, 0.89; 0.84-0.94; E-value, 1.4), and MACCE (HR, 0.86; 0.74-0.99; E-value, 1.5). No significant difference was observed for septic shock (HR, 0.87; 95% CI, 0.74-1.02), acute respiratory failure (HR, 0.94; 95% CI, 0.83-1.06), or MAKE (HR, 1.08; 95% CI, 0.92-1.27). The mortality benefit remained consistent through 365 days and across all prespecified subgroups. After Holm correction for multiple comparisons across the seven secondary outcomes, only the associations with MACE (adjusted P=0.012) and ICU admission (adjusted P<0.007) remained statistically significant, while those with MACCE, myocardial infarction, MAKE, septic shock, and acute respiratory failure did not. CONCLUSION: Among patients with T2D who developed sepsis, prior GLP-1RA use was associated with lower mortality and select cardiovascular/renal risks than prior SGLT2i use, though roughly half of secondary outcomes showed no significant difference. Exposure was defined at the drug-class rather than individual-agent level, and modest E-values alongside baseline imbalances before matching suggest residual confounding cannot be excluded. These hypothesis-generating findings warrant confirmation in prospective studies.

Drug design, development and therapy 2026 PubMed
03 "Younger Age is Associated with Treatment and Complication Outcomes Among Type 2 Diabetes Mellitus Patients in Kigali University Teaching Hospital" [Letter]. Dar MS et al. 10.2147/DMSO.S651927 Diabetes, metabolic syndrome and obesity : targets and therapy 2026 PubMed
04 Safety study of sitagliptin combined with metoprolol on the treatment of elderly patients with type 2 diabetes mellitus and hypertension. Dai X et al. 10.1515/med-2026-1538
View abstract

OBJECTIVES: Sitagliptin is a standard therapeutic option for type 2 diabetes mellitus (T2DM), while metoprolol is an antihypertensive agent. This study aimed to assess the safety of their combination therapy in elderly patients with T2DM and hypertension. METHODS: Medical data of 52 elderly patients with T2DM and hypertension from June 2021 to March 2024 were retrospectively collected. According to different treatment methods, 52 patients were categorized into the sitagliptin + metoprolol group (n=26) and the sitagliptin group (n=26). After a 12-week treatment period, the baseline characteristics, therapeutic efficacy and biochemical indicators were analyzed between groups. RESULTS: After 12-week treatment, both groups exhibited significant improvements in therapeutic efficacy, immune-inflammatory status, coagulation function, and liver-kidney function (p<0.05). Compared with the sitagliptin group, the sitagliptin + metoprolol group showed better therapeutic efficacy, with lower FPG, HbA, SBP, and DBP levels (p<0.05). The combination group also achieved greater improvements in immune-inflammation, coagulation, and liver-kidney function (lower CRP, NLR, Fib, Scr and BUN, as well as higher PT and APTT) (p<0.05). There was no significant difference in incidence of adverse event between the two groups (p>0.05). CONCLUSIONS: Short-term observation indicates that sitagliptin combined with metoprolol can improve blood glucose, blood pressure, inflammation, coagulation, and liver-kidney function in elderly patients with T2DM and hypertension, without a significant increase in the risk of adverse reactions during short-term follow-up. However, as a single-center, small-sample retrospective study, the present findings should be interpreted as preliminary clinical evidence.

Open medicine (Warsaw, Poland) 2026 Jan PubMed
05 Association Between Estimated Glucose Disposal Rate and Chronic Kidney Disease in Elderly Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study in Zhejiang, China. Chen X et al. 10.2147/CIA.S621766
View abstract

PURPOSE: To examine the association between estimated glucose disposal rate (eGDR) and study-defined chronic kidney disease (CKD) among elderly patients with type 2 diabetes mellitus (T2DM) in Zhejiang Province, China. METHODS: This cross-sectional study included 713 elderly T2DM patients (≥60 years) from Zhejiang Province, conducted between March and November 2018 as part of the China National Diabetic Chronic Complications Study. Study-defined CKD was operationally defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m and/or a urinary albumin-to-creatinine ratio (UACR) ≥30 mg/g. Multivariable logistic regression was used to assess the association of eGDR with study-defined CKD. Restricted cubic spline (RCS) analysis examined the shape of the association. Generalized additive models evaluated associations with UACR and eGFR, and receiver operating characteristic (ROC) analysis assessed discrimination. RESULTS: Among 713 participants, 245 (34.36%) met the study-defined CKD criteria. Each 1-unit increase in eGDR was associated with lower odds of study-defined CKD after multivariable adjustment (OR = 0.78, 95% CI: 0.70-0.86; p < 0.001). Compared with the lowest eGDR tertile, the adjusted ORs (95% CIs) were 0.51 (0.35-0.76) for the middle tertile and 0.31 (0.20-0.48) for the highest tertile (both p < 0.001). RCS analysis demonstrated an approximately linear inverse association between eGDR and study-defined CKD (p for nonlinearity > 0.05). eGDR was inversely associated with UACR (ρ = -0.277, p < 0.001) whereas the association between eGDR and eGFR was not statistically significant. The discriminative ability of eGDR for study-defined CKD was modest (AUC = 0.65, 95% CI: 0.61-0.70). The direction of the association was generally consistent across subgroups, with no significant interactions. CONCLUSIONS: Lower eGDR was associated with a higher prevalence of study-defined CKD in elderly patients with T2DM, with an approximately linear cross-sectional association. Prospective studies are needed to establish temporality and assess whether eGDR adds information beyond established CKD assessment.

Clinical interventions in aging 2026 PubMed
06 Identifying Patients with Rapid Progression to Diabetic Retinopathy in Type 2 Diabetes: A Simple Prediction Model for Community Settings. Zhao J et al. 10.2147/DMSO.S624132
View abstract

BACKGROUND: Diabetic retinopathy (DR) progression in community-based type 2 diabetes (T2D) remains challenging to predict. This multi-site cohort study aimed to identify novel metabolic risk factors beyond glucose control and develop a resource-adaptable model for prioritizing DR risk screening. METHODS: A prospective, multi-site study was conducted among patients with T2D from 2021 to 2023 across 14 community health centers in Northwestern China (Shaanxi). Baseline and follow-up data on demographic, medical history, and laboratory data were collected. DR was assessed by trained retinal specialists through fundus photography and slit-lamp bio-microscopy. LASSO-penalized logistic regression with 10-fold cross-validation was first performed to identify candidate predictors, followed by multivariable logistic regression to construct the prediction model. Model discrimination was evaluated using receiver operating characteristic (ROC) curve analysis and bootstrap internal validation. Clinical characteristics before and after onset of DR were analyzed using the paired-sample Wilcoxon test. RESULTS: Among 363 participants who completed follow-up, 50 (13.77%) patients developed DR. Patients who developed DR had longer duration of diabetes, higher HbA1c levels, poorer glycemic control, and elevated urine pH. Multivariate logistic regression identified HbA1c (OR = 1.30), urine pH (OR = 2.55), and diabetes duration (OR = 1.06) as independent risk factors. The prediction model showed moderate discrimination, with an apparent AUC of 0.72 and an optimism-corrected AUC of 0.693 after bootstrap internal validation. In paired analyses, patients exhibited significantly higher BUN and eGFR levels and lower serum creatinine after DR onset (all P < 0.05). CONCLUSIONS: In this community-based cohort, a prediction model incorporating urine pH, HbA1c, and diabetes duration showed potential for identifying individuals at high risk of incident DR. Urine pH may serve as a simple and accessible metabolic marker for risk stratification, while renal functional alterations may reflect early systemic changes beyond glycemic control.

Diabetes, metabolic syndrome and obesity : targets and therapy 2026 PubMed
07 When Current Severity Overrides Reassuring Findings: TG18-Guided Biliary Drainage in ERCP-Confirmed Purulent Cholangitis. Taha HM et al. 10.1002/ccr3.73674
View abstract

A 42-year-old antibiotic-naïve man with previous laparoscopic cholecystectomy and poorly controlled type 2 diabetes mellitus (HbA1c 9.7%) presented with Charcot's triad 7 days after a formally documented normal hepatobiliary evaluation (alanine aminotransferase [ALT] 22 U/L; total bilirubin 0.7 mg/dL [12 μmol/L]; common bile duct [CBD] ≤ 5 mm on ultrasound). Admission findings satisfied all three Tokyo Guidelines 2018 (TG18) diagnostic domains. Severity was Grade II on two of the five TG18 severity criteria-leukocytosis (14.2 × 10/μL) and hyperbilirubinaemia (26 mg/dL, 445 μmol/L); temperature (38.9°C), age (42 years), and albumin (3.4 g/dL, 34 g/L) did not meet their thresholds, and no Grade III organ dysfunction was identified on the recorded variables. Grade II severity established the indication for early biliary drainage at presentation. Computed tomography (CT) showed only mild intrahepatic ductal dilatation with 3-4 hyperattenuating distal CBD filling defects (greatest ≈4 mm) and no dominant calculus. Immediate endoscopic retrograde cholangiopancreatography (ERCP) was not feasible because of endoscopy-suite and anesthetic availability; antimicrobial and supportive therapy continued, and persistent clinical and biochemical abnormalities at 48 h (ALT 837 U/L; bilirubin 24 mg/dL, 410 μmol/L; C-reactive protein 86 mg/L) reinforced the urgency of drainage during that interval. ERCP on Day 3, at the earliest available opportunity, showed macroscopic purulent bile at ductal entry, distal CBD filling defects, and copious biliary sludge on balloon sweep. Fever resolved within 24 h, and hepatobiliary and inflammatory markers normalized by 3 months (ALT 38 U/L; bilirubin 0.9 mg/dL, 15 μmol/L; C-reactive protein < 5 mg/L). This case illustrates that current severity, not antecedent normality or unimpressive imaging, should govern the timing of biliary drainage, and it reports transparently an interval to drainage imposed by resource availability.

Clinical case reports 2026 Oct PubMed
08 Microbiome signatures and mechanistic pathways in pediatric obesity: from early-life risk to precision interventions. Xie SS et al. 10.1007/s12519-026-01094-7
View abstract

BACKGROUND: The gut microbiota is increasingly recognized as a modulator of metabolic health in children, influencing nutrient absorption, immune tone, epithelial barrier function, and energy homeostasis. This review summarizes current evidence on microbial signatures and mechanistic pathways associated with pediatric obesity and evaluates microbiota-targeted strategies for prevention and intervention. DATA SOURCES: Relevant studies published between January 2000 and February 2026 were identified through searches of PubMed, Embase, and Web of Science using keywords related to pediatric obesity, gut microbiota, microbial metabolites, and microbiota-based interventions. Human studies and mechanistic animal models examining host-microbe metabolic interactions were included. RESULTS: Pediatric obesity is associated with shifts in gut microbial composition, although taxonomic findings are heterogeneous across studies and should not be interpreted as universal biomarkers. Relatively consistent patterns include reduced Bifidobacterium and Akkermansia muciniphila, whereas associations involving Faecalibacterium, Blautia, and lactobacilli are context-, species-, and strain-dependent. Functional alterations include changes in short-chain fatty acid production, bile acid signaling, microbial branched-chain and aromatic amino acid metabolism, and endotoxin-related inflammatory pathways. The enrichment of Gram-negative taxa such as Enterobacteriaceae may contribute to impaired epithelial barrier integrity, lipopolysaccharide translocation, toll-like receptor 4 signaling, chronic low-grade inflammation, and insulin resistance. Early-life exposures, including cesarean delivery, formula feeding, and antibiotic use, are repeatedly associated with altered microbial succession and later obesity risk, although causality remains incompletely defined. Interventional studies indicate that dietary fiber enrichment and selected probiotic strains can improve microbial and metabolic outcomes in some settings, but efficacy remains strain-specific and clinically heterogeneous. CONCLUSIONS: Microbial and metabolic signatures are associated with pediatric obesity, converging on pathways of energy harvest, epithelial barrier dysfunction, inflammation, and disrupted host-microbe signaling. Integrative multi-omic and longitudinal studies are required to establish causality and guide the development of personalized, microbiota-based interventions for obesity prevention and treatment in children.

World journal of pediatrics : WJP 2026 Oct 3 PubMed
09 Sex, Racial/Ethnic, and Regional Disparities in Mortality Involving Both Cardiac Arrest and Type 2 Diabetes Mellitus Among U.S. Adults, 1999-2020. Chaudhary A et al. 10.1007/s40615-026-03215-4
View abstract

AIMS: Type 2 Diabetes mellitus (T2DM) and cardiac arrest (CA) drive significant mortality and healthcare costs in the U.S., yet national trends and disparities remain unclear. This study aims to evaluate national trends in mortality involving concurrent T2DM and CA among the U.S. adult population. METHODS: Using Centers for Disease Control and Prevention Wide Ranging Online Data for Epidemiologic Research (CDC WONDER) database, we analyzed deaths among U.S. adults aged ≥ 25 (1999-2020) from T2DM (ICD-10: E11) and CA (ICD-10: I46), calculating crude and age-adjusted mortality rates (AAMR) per 100,000 and estimating annual percent change (APC) via Joinpoint regression stratified by sex, race/ethnicity, age and geography. RESULTS: Between 1999 and 2020, 258,675 deaths involving both T2DM and CA occurred. AAMRs increased from 1999 to 2014 (APC 2.72) and surged through 2020 (APC 9.55). Mortality was higher in men than in women (AAMR 6.75 vs. 4.36). Marked racial and ethnic disparities were observed, with the highest mortality rates among Hispanic (AAMR 10.92) and non-Hispanic (NH) American Indian/Alaska Native populations (10.16), while NH Whites had the lowest rates (4.35). The sharpest increases in AAMR were observed in younger adults. Geographically, the Western region and metropolitan areas exhibited the highest mortality burden. At the state level, California had the highest AAMR, whereas Maryland had the lowest. CONCLUSIONS: Mortality related to coexisting T2DM and CA increased substantially in the United States from 1999 to 2020, with an accelerated rise after 2014, particularly among younger adults and ethnic minorities. These findings highlight an urgent need for targeted cardiovascular preventive strategies in these high-risk cohorts.

Journal of racial and ethnic health disparities 2026 Oct 3 PubMed
10 Ru3: a novel ruthenium-based compound overcomes cisplatin resistance in non-small cell lung cancer via the E2F2-IGFBP3-GPX4 pathway. Lu Y et al. 10.1007/s10495-026-02447-3
View abstract

Cisplatin resistance remains a major hurdle in non-small cell lung cancer (NSCLC) treatment. Here, we designed and synthesized a novel ruthenium-based compound, which selectively kills cisplatin-resistant NSCLC cells while sparing parental cells. Mechanistically, Ru3 triggers mitochondrial damage and reactive oxygen species (ROS) accumulation. In addition, it upregulates the transcription factor E2F2, which directly represses IGFBP3 expression. IGFBP3 normally scavenges ROS via the GPX4 system; thus, E2F2-mediated IGFBP3 suppression disrupts this antioxidant defense, exacerbating ROS levels and cell death. Notably, cisplatin-resistant cells exhibit elevated GPX4 and IGFBP3 expression, making them particularly vulnerable to Ru3. This study elucidates the E2F2-IGFBP3-GPX4 axis as a novel therapeutic vulnerability and highlights Ru3 as a promising agent for refractory NSCLC.

Apoptosis : an international journal on programmed cell death 2026 Oct 3 PubMed
11 BAF60A governs beta cell identity to control systemic glucose homeostasis. Zhu S et al. 10.1007/s00125-026-06884-2
View abstract

AIMS/HYPOTHESIS: Chromatin remodelling is critical for maintaining pancreatic beta cell identity and function, yet the key regulatory mechanisms remain incompletely defined. This study aimed to investigate the role of the switch/sucrose non-fermentable (SWI/SNF) complex subunit BAF60A in preserving beta cell fate and glucose homeostasis. METHODS: Pdx1-Cre-mediated BAF60A-knockout (BaBKO) and BAF60A-overexpressing (BaBOE) mice, together with tamoxifen-inducible adult beta cell-specific Smarcd1 knockout (BaBKO) and Isl1 knockout (Isl1BKO) mice, were generated to evaluate the role of BAF60A in vivo. Glucose homeostasis was assessed through glucose tolerance tests, insulin tolerance tests and glucose-stimulated insulin secretion (GSIS) assays. Multiomic analyses, including RNA-seq, ATAC-seq, Cleavage Under Targets and Tagmentation (CUT&Tag) and single-cell RNA-seq, were performed to characterise chromatin accessibility and transcriptional changes. BAF60A-interacting proteins were identified with biotin identification (BioID) and GST pull-down assays. Beta cell lineage tracing was used to assess changes in cell identity. In addition, BAF60A and the dedifferentiation marker ALDH1A3 were examined in pancreatic islets from individuals with and without type 2 diabetes. RESULTS: BaBKO mice exhibited significant glucose intolerance, impaired GSIS and pronounced loss of beta cell identity, accompanied by the acquisition of non-beta endocrine features. Inducible deletion of Smarcd1 in adult beta cells similarly impaired beta cell maturation and promoted dedifferentiation, as confirmed by lineage tracing. BAF60A deficiency reduced enhancer accessibility and downregulated beta cell identity genes. Mechanistically, BAF60A physically interacts with the transcription factor islet-1 (ISL1) to regulate transcription of target genes. Adult beta cell-specific Isl1 deletion recapitulated key features of BAF60A deficiency and abolished the beneficial effect of BAF60A overexpression on insulin secretion. Conversely, BaBOE mice exhibited improved glucose tolerance and enhanced GSIS under high-fat diet conditions. Adeno-associated virus-mediated BAF60A overexpression markedly reduced beta cell dedifferentiation in BKS-db/db mice. In human type 2 diabetes islets, BAF60A expression was significantly reduced and inversely correlated with ALDH1A3. CONCLUSIONS/INTERPRETATION: This work establishes BAF60A-ISL1-dependent chromatin remodelling as a key mechanism that preserves beta cell identity and function under metabolic stress, providing mechanistic insight into beta cell failure in type 2 diabetes.

Diabetologia 2026 Oct 3 PubMed
12 Adipocyte-derived exosomal ANGPTL2 promotes beta cell dysfunction via the EIF2α/ATF4/CHOP stress pathway in mice. Zhong X et al. 10.1007/s00125-026-06885-1
View abstract

AIMS/HYPOTHESIS: Obesity-associated lipotoxicity drives beta cell failure in type 2 diabetes, but the adipose-to-islet signals that promote beta cell dysfunction remain incompletely defined. We hypothesised that angiopoietin-like protein 2 (ANGPTL2) carried by lipotoxic adipocyte-derived exosomes contributes to adipose-to-islet signalling that impairs beta cell function. METHODS: Exosomes from palmitate- or PBS-treated 3T3-L1 adipocytes were applied to MIN6 cells and primary mouse islets to assess beta cell function and identity. In vivo, mice underwent adipose-specific Angptl2 knockdown under high-fat diet (HFD) feeding, followed by metabolic phenotyping and assessment of beta cell function. Adipose-derived exosomes from HFD-fed mice with or without adipose Angptl2 knockdown were injected into normal-chow-fed recipient mice, and endocrine marker composition and islet secretory function were evaluated. Mechanistic studies in MIN6 cells used co-immunoprecipitation, pharmacological rescue experiments and Eif2α (also known as Eif2s1) knockdown to interrogate stress signalling. RESULTS: Exosomes derived from palmitate-treated adipocytes were efficiently internalised by beta cells and resulted in impaired insulin content and secretion, accompanied by reduced beta cell identity markers and induction of dedifferentiation signatures. ANGPTL2 was enriched in lipotoxic adipocyte-derived exosomes and accumulated in beta cells in an exosome-dependent manner. Angptl2 silencing in adipocytes lowered exosomal ANGPTL2 and mitigated islet dysfunction in vitro. In vivo, adipose-specific Angptl2 knockdown reduced islet ANGPTL2 without changing islet Angptl2 mRNA and improved glucose tolerance, with the AUC of the IPGTT decreasing from 2300.2 ± 165.5 to 1583.7 ± 88.8 mmol/l × min (mean ± SD). In adipose-exosome transfer experiments, recipients of HFD-short hairpin (sh)Angptl2-exosome (Exo) showed lower islet ANGPTL2 abundance and improved ex vivo islet glucose-stimulated insulin secretion (GSIS), with stimulated insulin secretion increasing from 6.0 ± 0.3% (mean ± SD) in the HFD-sh-negative control (NC)-Exo group to 10.9 ± 0.6% in the HFD-shAngptl2-Exo group. Mechanistically, ANGPTL2 associated with eukaryotic translation initiation factor 2α (EIF2α) and increased protein kinase R-like endoplasmic reticulum kinase (PERK)-associated EIF2α by approximately 2.8-fold, whereas this difference was lost after further normalisation to input EIF2α, supporting a substrate-availability model. PERK inhibition and integrated stress response inhibitor both attenuated ANGPTL2-induced activating transcription factor-4 (ATF4)/C/EBP homologous protein (CHOP) signalling and improved GSIS. CONCLUSIONS/INTERPRETATION: Lipotoxic adipocyte-derived exosomes increase ANGPTL2 abundance in recipient beta cells and contribute to beta cell dysfunction and identity disruption by amplifying PERK-dependent EIF2α/ATF4/CHOP signalling. Adipose ANGPTL2 and circulating exosome-associated ANGPTL2 represent candidate targets and biomarkers for preserving beta cell function in obesity-associated dysglycaemia.

Diabetologia 2026 Oct 3 PubMed
13 MIND-T1D: study protocol for a multidimensional neurocognitive and psychological assessment of Indian children and young adults with type 1 diabetes. Wagle-Patki S et al. 10.1136/bmjpo-2026-005159
View abstract

BACKGROUND: Type 1 diabetes mellitus (T1D) is increasingly recognised to affect neurodevelopmental, cognitive and psychological functioning in children and young adults. Existing studies have largely evaluated biological, cognitive and psychological domains separately, and neuropsychological approaches suitable for multilingual and resource-constrained settings remain limited. This paper describes the MIND-T1D protocol, a culturally sensitive, clinically feasible, family-centred assessment framework for Indian children and young adults with T1D. The protocol addresses language-related barriers and educational variability by incorporating neuropsychological assessments and integrating child, parent and biological assessments within a single framework. METHODS AND ANALYSIS: MIND-T1D is a cross-sectional analytical study conducted at a tertiary diabetes centre in Western India. Individuals aged 10-21 years with T1D (n=264) and healthy sibling controls (n=132) frequency matched by age group will be recruited. The protocol integrates neuropsychological assessment, behavioural and emotional evaluation, health-related quality of life, parental psychological assessment, glycated haemoglobin (HbA1c) and brain-derived neurotrophic factor (BDNF) estimation. Neuropsychological measures are organised in a structured sequence to maintain participant engagement and minimise assessment burden. The primary objective is to compare neurocognitive functioning between participants with T1D and healthy sibling controls. Secondary objectives include evaluation of behavioural and emotional functioning, health-related quality of life and parental psychological characteristics. Exploratory objectives include examining associations of HbA1c and serum BDNF levels with neurocognitive and psychological outcomes. Sample size provides approximately 80% power to detect small-to-moderate group differences at a two-sided significance level of 0.05. Statistical analyses will include group comparisons and multivariable regression models adjusting for relevant covariates. TRIAL REGISTRATION NUMBER: NCT07164768.

BMJ paediatrics open 2026 Oct 3 PubMed
14 Development and Evaluation of a Trauma-Informed Women's Health Education Program for Intimate Partner Violence Survivors: A Mixed-Methods Study. Joseph S et al. 10.1891/VV-2025-0100
View abstract

Women with a history of intimate partner violence (IPV) are at increased risk for cardiovascular disease, human papillomavirus (HPV), cervical cancer, and human immunodeficiency virus (HIV), which we collectively termed women's health issues (WHIs). This study aimed to educate IPV survivors through a trauma-informed, WHI education program tailored to the needs and experiences of IPV victims, based on focus group data. An education program was created using data from 10 focus groups ( = 38), and these interactive presentations on WHIs were presented to IPV survivors ( = 69). Participants completed demographic surveys, including questions about physician acknowledgment of IPV as a risk factor for chronic conditions, and pre-post tests to evaluate the effectiveness of the educational sessions. Education session data revealed that 39% of participants had never heard of HPV, 38% had not received a Pap smear in the last 3 years, and 15% did not know where to get tested for HIV. Only 15% ( = 10) of participants reported that their physician acknowledged IPV as a risk factor for disease. Following the health education, there was a significant normalized gain of 55.66%, with paired tests comparing pretest/posttest scores supporting understanding of WHIs ( < .01). Tailored education modules about WHIs proved effective in educating women who have experienced IPV. Future iterations will focus on topics informed by participant responses, such as diabetes mellitus, neurological disorders, reproductive health, and gastrointestinal diseases. This study opens avenues for further exploration of the connection between IPV and health initiatives.

Violence and victims 2026 Oct 3 PubMed
15 Hospitalization outcomes in adults with type 2 diabetes mellitus treated with once-weekly insulin efsitora versus once-daily basal insulins: A post hoc analysis of the QWINT-1 to -4 randomized trials. Philis-Tsimikas A et al. 10.1016/j.diabres.2026.113586
View abstract

AIMS: To describe hospitalization and associated outcomes using pooled data from QWINT-1-4 trial participants. METHODS: The multicenter, open-label, treat-to-target phase 3 QWINT-1 through QWINT-4 clinical trial program randomized adults with type 2 diabetes mellitus (T2D) toonce-weekly insulin efsitora alfa (efsitora)versus once-daily basal insulin comparators (insulin glargine: QWINT-1, QWINT-4; insulin degludec: QWINT-2, QWINT-3). This exploratory, post hoc analysis pooled data from QWINT-1-4 trials of participants receiving once-weekly efsitora(N = 1883) or once-daily basal insulin comparators (comparators, N = 1556). Unadjusted summary statistics by treatment group are reported for hospitalization incidence, duration of hospital stay, treatment discontinuation, glycated hemoglobin (HbA), insulin doses, and hypoglycemia rates. RESULTS: Overall, 173 (9.2 %) participants receiving once-weekly efsitora and 110 (7.1 %) receiving once-daily comparators (p = 0.17) were hospitalized. The duration of hospital stay was numerically similar for participants receiving efsitora (median 5.0 days) or comparators (median 5.0 days). Permanent treatment discontinuation, primarily driven by adverse events, was more frequent among efsitora-treated (26.6 %) than comparator-treated (16.4 %) participants (p = 0.03). Mean HbA, insulin doses, and hypoglycemia rates before and after hospitalization were numerically similar in both groups. CONCLUSIONS: Once-weekly efsitora or once-daily insulin treatment does not appear to impact duration of hospitalization or glycemic parameters before or after hospitalization. CLINICALTRIALS: govidentifiers: NCT05662332 (QWINT-1), NCT05362058 (QWINT-2), NCT05275400 (QWINT-3), NCT05462756 (QWINT-4).

Diabetes research and clinical practice 2026 Oct 3 PubMed
16 Assessment of Dressing Method (Self-dressing vs. Nurse-led dressing) on Healing Outcomes in Diabetic Foot Ulcers: A Prospective Comparative Study. Mohammed IB et al. 10.1016/j.avsg.2026.09.035
View abstract

BACKGROUND: Diabetic foot ulcers (DFUs) are a major cause of morbidity and amputation. Professional wound care is standard, but patient self-dressing could be an alternative in resource-limited settings. Direct comparisons between self-dressing and nurse-led dressing are lacking. We compared their effects on healing outcomes in DFUs. METHODS: This prospective, randomized, controlled trial enrolled 60 adults (≥18 years) with type 1 or type 2 diabetes and Wagner grade 1-2 DFUs, ankle-brachial index ≥0.7, sufficient cognitive and motor skills for self-care, and ability to attend follow-up. Patients were randomized 1:1 to either a structured self-dressing protocol after standardized training (group A, n=30) or nurse-led dressing (group B, n=30). All received standardized offloading, debridement, and a sodium hyaluronate dressing changed every 2-3 days. The primary outcome was time to complete healing (weeks). Secondary outcomes included healing rate, infection, amputation, and number of dressing days. Follow-up for healing outcomes was 14 weeks. Analysis used intention-to-treat, with post-hoc logistic regression adjusting for baseline imbalances. RESULTS: Baseline characteristics were similar except for higher chronic kidney disease prevalence and foot infection score in the self-dressing group (P<0.05). After adjusting for these factors, the dressing type remained independently associated with complete healing (adjusted OR 0.12, 95% CI 0.02-0.68, P=0.016). Healing of surface area and wound volume was significantly slower in the self-dressing group at all time points from 2 to 14 weeks (P<0.001). Complete healing occurred in 80.0% (24/30) of the self-dressing group vs. 100% (30/30) of the nurse-led group (P=0.032). Time to complete healing was longer with self-dressing (mean 17.7±4.1 vs. 9.8±2.1 weeks; P<0.001). Dressing days (124.8±28.2 vs. 67.7±15.3; P<0.001), infection rate (23.3% vs. 0%; P=0.011), and minor amputations (17.9% vs. 0%; P=0.021) were significantly higher in the self-dressing group. Limb salvage and major amputations did not differ significantly. CONCLUSIONS: In patients with uncomplicated DFUs, nurse-led dressing achieved faster healing, fewer infections, and fewer minor amputations compared with structured patient self-dressing. Self-dressing cannot be recommended as a substitute for professional wound care in this population.

Annals of vascular surgery 2026 Oct 3 PubMed
17 Nisotirostide (LY3457263), a novel NPY2 receptor agonist for type 2 diabetes and obesity: From discovery to clinical proof of concept. Briere DA et al. 10.1016/j.molmet.2026.102452
View abstract

BACKGROUND/OBJECTIVE: Nisotirostide is a novel selective NPY2 receptor agonist under development as adjunctive therapy for people with type 2 diabetes (T2D) on glucagon-like peptide-1 receptor agonists (GLP-1 RA). METHODS: Nisotirostide binding affinity and potency were determined against human NPY2 receptor. Effects of nisotirostide on body weight, food intake, body composition, glucose, and insulin were evaluated in mouse models. A Phase 1 study in healthy participants and participants with T2D on 1.5 mg once-weekly dose of dulaglutide evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics, following a single subcutaneous dose of nisotirostide ranging from 0.025 to 1 mg. RESULTS: Nisotirostide potently and selectively activated NPY2 receptor signaling in vitro. In mice, nisotirostide reduced body weight by up to 12% as monotherapy and up to 31% when combined with GLP-1 RA, demonstrating synergism. Nisotirostide-treated mice showed improved glucose control, independent of weight loss. In Phase 1 clinical study (N=65), PK of nisotirostide supported a once-weekly dosing regimen. A 1 mg dose of nisotirostide in monotherapy reduced mean body weight by 0.75 kg versus placebo (ns); when added to dulaglutide, up to 2.58 kg reduction was observed versus dulaglutide alone (p<0.05). Gastrointestinal adverse events, such as nausea and vomiting, were the most commonly reported with nisotirostide; these were dose-dependent and mild-to-moderate in severity. CONCLUSION: Nisotirostide demonstrated potent, selective NPY2R agonism with a PK profile supporting once-weekly dosing. Preclinical metabolic benefits, including weight-independent glucose improvements, translated clinically, and a manageable tolerability profile supports further development as adjunctive GLP-1 RA therapy for T2D and obesity. GOV NUMBER: NCT04641312.

Molecular metabolism 2026 Oct 3 PubMed
18 Chemometrics-assisted FTIR and machine learning for biochemical profiling of human skeletal muscles in relation to type 2 diabetes. Abdelmonaem MEA et al. 10.1016/j.saa.2026.128893
View abstract

Skeletal muscle is the major site of insulin-stimulated glucose uptake, making it highly susceptible to metabolic disorders. This study investigates Type 2 diabetes mellitus-associated alterations in the macromolecular composition of functionally distinct human skeletal muscles. These modifications are crucial to understanding the molecular basis of diabetic myopathies but remain underexplored. Five skeletal muscles from 80 individuals (40 controls and 40 individuals with Type 2 diabetes) were analysed. To overcome the limitations of traditional histochemical assays, we employed infrared spectroscopy combined with a chemometric decomposition approach to resolve spectra into five spectral components, each dominated by a specific macromolecular group. The corresponding component weights quantified and compared relative macromolecular proportions between the diabetic and control groups for different muscle types. Compared with controls, muscles from individuals with diabetes showed a consistent pattern of higher lipid levels and lower glycogen levels, with a statistically significant increase in lipids within the diaphragm. This biochemical profiling was enriched by building machine learning classifiers, which achieved low-to-modest but statistically significant AUC performance of up to 72% (p < 0.05) in discriminating diabetic from healthy muscle. Our work demonstrates an efficient methodology for the simultaneous screening of various macromolecular constituents using spectral data obtained in a single experiment. It provides medically relevant insights into the biological patterns of diabetes-associated skeletal muscle remodelling to guide future research. However, an independent validation should be performed to overcome this study limitation and draw definitive conclusions.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 2026 Sep 28 PubMed
19 Gut dysbiosis, blood pressure regulation, and cardiometabolic risk in polyendocrine metabolic ovarian syndrome (PMOS). Naveed M et al. 10.1007/s11154-026-10085-y
View abstract

Polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), is a common endocrine-metabolic disorder associated with increased hypertension and cardiometabolic risk. Gut dysbiosis is also frequently reported in affected women, raising the question of whether microbiome-linked pathways contribute to blood pressure elevation or vascular risk in this syndrome. To evaluate and synthesize the available evidence linking gut dysbiosis, gut microbial function, and microbiome-related mechanisms to hypertension, blood pressure regulation, and cardiovascular risk in women with PMOS, we conducted a narrative review of the literature in PubMed, Scopus, Web of Science, Google Scholar, and citation tracking. Search terms included PCOS, PMOS, gut microbiota, gut dysbiosis, hypertension, blood pressure, cardiovascular risk, microbial metabolites, bile acids, intestinal permeability, inflammation, renin-angiotensin signaling, renal sodium handling, and autonomic regulation. Human studies, animal models, interventional studies, and mechanistic investigations relevant to PMOS and hypertension were reviewed according to predefined inclusion and exclusion criteria. Eligible publications were preclinical studies, human studies, English language, adult females, and peer-reviewed original or review articles. Clarifying whether gut dysbiosis contributes to hypertension in PMOS may improve understanding of the mechanisms underlying cardiometabolic risk in affected women and inform the development of microbiome-targeted diagnostic and therapeutic strategies. Achieving this goal will require well-phenotyped clinical studies integrating PMOS, blood pressure and vascular assessments with functional microbiome analyses.

Reviews in endocrine & metabolic disorders 2026 Oct 3 PubMed
20 Prevalence, risk factors and adverse health outcomes of osteosarcopenia in middle-aged and older adults with type 2 diabetes mellitus-a scoping review. Tan AWK et al. 10.1007/s00198-026-08228-7
View abstract

Osteoporosis and sarcopenia are increasingly recognised as important complications of type 2 diabetes mellitus (T2D). As both conditions share common pathophysiological mechanisms, they can coexist in the same individual. The coexistence of osteoporosis and sarcopenia, known as osteosarcopenia (OS), is an emerging geriatric syndrome. Compared with its individual components, OS has received much less attention. The overall objective of this scoping review was to summarise the existing literature on the prevalence, risk factors, biomarkers, and adverse health outcomes associated with OS in adults with T2D aged ≥ 40. A search was conducted in eight online databases (Ovid MEDLINE®, Embase (Ovid), PubMed, CINAHL, Cochrane Library, Web of Science, Scopus and PsycINFO) and grey literature sources for relevant articles published in English up to 31 July 2024. A total of ten articles reporting findings from nine distinct studies (7 cross-sectional, 2 case-control) were included. Despite significant heterogeneity in its definition, OS was shown to be prevalent in T2D. The risk of OS was increased in individuals with T2D who had poor β-cell function, low body mass index, and smaller waist circumference. Insulin resistance, duration of T2D, glycaemic control, and metformin, sulfonylurea and insulin use were not shown to be significant risk factors. Osteocalcin was a potentially useful biomarker of OS in T2D, and OS may be associated with falls and leg fractures in T2D. In conclusion, this scoping review revealed a paucity of information about OS in T2D. Longitudinal studies with comprehensive phenotyping are required to address the many knowledge gaps.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2026 Oct 3 PubMed
21 Refractory diabetic ketoacidosis in Rabson-Mendenhall syndrome due to a novel mutation: contrasting outcomes in a sibling - case series. Azarudeen JM et al. 10.1515/jpem-2026-0389
View abstract

OBJECTIVES: Rabson-Mendenhall syndrome (RMS) is a rare monogenic insulin resistance disorder characterized by progressive dysglycemia and early mortality. Management of diabetic ketoacidosis (DKA) in RMS is particularly challenging because standard insulin doses may be inadequate, and pediatric-specific experience is limited. CASE PRESENTATION: We report two siblings with genetically confirmed RMS. The index child, a 7-year-old girl, presented with severe refractory DKA requiring progressive escalation of intravenous insulin to 12 IU/kg/h before meaningful metabolic response was achieved. Insulin was titrated according to serial glycemic and acid-base responses, without bicarbonate therapy, with close potassium monitoring. Her 3-year-old brother was evaluated proactively after the diagnosis in his sister and was found to have hyperglycemia and the same homozygous variant before an episode of metabolic decompensation. He was treated with subcutaneous insulin and insulin sensitizers. At 1-year follow-up, HbA was 10.4 % in the index child and 8.9 % in the sibling. CONCLUSIONS: Refractory DKA in RMS may require rapid, response-guided escalation of insulin beyond conventional pediatric dosing. The detailed temporal relationship between insulin dose and metabolic response in this child provides practical clinical insight, while early recognition of RMS permits evaluation and treatment of affected siblings before presentation with acute metabolic decompensation.

Journal of pediatric endocrinology & metabolism : JPEM 2026 Oct 5 PubMed
22 Indications and pathways of Type 2 diabetes mellitus as a predictor of neurocognitive decline and dementia: Clinical implications and management. Megari K et al. 10.1080/23279095.2026.2741894
View abstract

Type 2 diabetes mellitus (T2DM) is a metabolic disease, one of the most common chronic conditions globally. Studies suggest that T2DM can increase the risk of mild cognitive impairment (MCI), Alzheimer's disease (AD) and other types of dementia; T2DM has been associated with decline in memory, verbal fluency, executive function and processing speed. It seems that T2DM and AD share common biological mechanisms. Multiple studies have investigated them, suggesting that insulin resistance, hyperglycemia and neuroinflammation are some potential factors which can increase risk of dementia in patients with T2DM. Thus, it is suggested that cognitive screening in the early stages of T2DM can be beneficial to prognose disease progression. Despite the current data regarding T2DM and dementia, there is a research gap on interventions focusing on the cognitive and psychological aspects of diabetes. Therefore, future studies should focus on creating tailored interventions for diabetic patients and identify possible biomarkers for the early prediction of cognitive deficits on T2DM. With a deeper understanding, researchers can help prevent or delay cognitive impairment in patients with T2DM contributing to patient's quality of life and the broader landscape of public health.

Applied neuropsychology. Adult 2026 Oct 3 PubMed
23 Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa: A nationwide cohort study. Nielsen VW et al. 10.1111/jdv.70769
View abstract

BACKGROUND: Hidradenitis suppurativa (HS) is associated with obesity, metabolic dysfunction and increased healthcare utilization. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated anti-inflammatory effects and reduction in HS symptoms, but real-world patterns of GLP-1RA use in HS remain limited. OBJECTIVES: To investigate GLP-1RA use and comorbidity burden among patients with HS compared to matched psoriasis patients and background controls, including changes in healthcare utilization and treatment patterns following GLP-1RA initiation. METHODS: In this nationwide Danish register-based cohort study, adult patients with HS and age- and sex-matched patients with psoriasis and background controls were included from 1 January 2000 to 31 December 2022. Comorbidities were assessed at the date of HS diagnosis (index date) and at GLP-1RA initiation. Healthcare utilization, surgical procedures and medication use were examined during the 2 years before and after GLP-1RA initiation among patients with HS receiving continuous GLP-1RA treatment and matched HS non-users. RESULTS: A total of 12,581 patients with HS, 9824 patients with psoriasis, and 12,581 controls were included. During follow-up, 8.2% of patients with HS initiated GLP-1RA treatment, compared with 5.7% of psoriasis patients and 3.2% of controls. Mean time to GLP-1RA initiation was shorter among patients with HS (8.88 years) than psoriasis patients (10.1 years; p < 0.001) and controls (10.2 years; p < 0.001). Cardiometabolic and psychiatric comorbidities increased from index date to treatment initiation across all groups. Following GLP-1RA initiation, lower rates of surgical procedures and systemic medication use were observed. CONCLUSIONS: Patients with HS demonstrated earlier and more frequent use of GLP-1RA compared with psoriasis patients and controls, with decreased use of HS-specific treatments and surgical procedures following GLP-1RA initiation. Comparable declines were observed among matched non-initiators.

Journal of the European Academy of Dermatology and Venereology : JEADV 2026 Oct 3 PubMed
24 Prevalence of binge eating disorder symptoms and associated characteristics in Danish adults with type 2 diabetes: A cross-sectional study. Nybo PF et al. 10.1111/dme.70489
View abstract

AIMS: Coexistence of binge eating disorder (BED) and type 2 diabetes is linked to poor health outcomes, but data on the prevalence and clinical profile of BED symptoms remain limited and inconsistent. We estimated the prevalence of BED symptoms and examined their associated clinical characteristics in Danish adults with type 2 diabetes. METHODS: We conducted a cross-sectional study within the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) cohort. Adults with type 2 diabetes completed the Binge Eating Disorder Questionnaire (BED-Q) to determine the presence of BED symptoms. Data on well-being, comorbidities, treatment and biomarkers were retrieved from national health registers. Associations between participant characteristics and BED symptoms were examined using Poisson regression to estimate prevalence ratios (PRs). RESULTS: Among 2459 individuals, 72 (2.9%) screened positive for BED symptoms, and 76 (3.1%) showed subclinical BED symptoms. Individuals with BED symptoms had an earlier age at diagnosis of type 2 diabetes (median 51.8 years, IQR: 41.3-57.6) than adults without BED symptoms (median 59.5 years, IQR: 52.1-66.2). BED symptoms were also associated with severe obesity (BMI ≥35 kg/m) (PR 11.37, 95% CI: 2.78-46.49), female sex (PR 1.54, 95% CI: 1.12-2.10), and lower well-being (PR 1.83, 95% CI: 1.15-2.92). CONCLUSIONS: BED symptoms were associated with a distinct clinical and psychosocial profile in Danish adults with type 2 diabetes. These findings support clinical awareness of BED symptoms in this population, particularly among women, individuals with obesity, those with lower well-being and those diagnosed with diabetes at a younger age.

Diabetic medicine : a journal of the British Diabetic Association 2026 Oct 3 PubMed
25 Leucine Mitigates Diabetic Nephropathy via Its Antioxidant Effect and Modulation of TGF-β/SMAD-3 Signalling Pathway in Streptozotocin-Induced Diabetic Rats. Merdas ZJH et al. 10.2147/DDDT.S619144
View abstract

BACKGROUND/OBJECTIVES: Diabetic nephropathy (DN) is the main contributor to the incidence of end-stage renal disease and kidney failure. This research aims to explore the curative effect of leucine in the DN rat model. METHODS: 40 male rats were sorted into four equal groups. Group I acted as the control group. Group II was given leucine (1.35g/kg orally, once daily) for 8 weeks. Group III administered a single intraperitoneal injection of Streptozotocin (STZ) (45 mg/kg, i.p.). Group IV was administered leucine following the diagnosis of diabetes for a duration of 8 weeks. In this study, samples were obtained from blood and renal tissue for biochemical assessments, evaluation of redox state, real-time polymerase chain reaction (RT-PCR) analysis of L-type amino acid transporter 1 (LAT1) and suppressor of Mothers against Decapentaplegic (SMAD3) genes, as well as histological examination. RESULTS: Leucine supplementation to diabetic rats markedly reduced alterations in markers of kidney function. Furthermore, a reduction in redox markers and inflammatory cytokines was observed in tissues isolated from the leucine-treated diabetic group compared with diabetic rats. Additionally, the expression of the SMAD3 gene, mTOR, and c-JNK protein in renal tissue was significantly reduced in the leucine-diabetic group compared with the diseased group. Conversely, LAT1 tissue expression was upregulated in the leucine-diabetic group. CONCLUSION: The administration of leucine inhibited renal damage by reducing activation of the profibrotic transforming growth factor beta-1 TGF-β/Smad3 signalling pathway.

Drug design, development and therapy 2026 PubMed
26 Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases Fanjing Kong et al. 10.1038/s41467-025-67701-9 29 citations Nature Communications 2026 Scholar
27 Beyond Glycemic Control: Tirzepatide in a Woman With Prior Gestational Diabetes and High Cardiometabolic Risk A. Carducci 10.63620/mkjgomh.2026.1047 Journal of Gynecology Obstetrics and Mother Health 2026 Scholar
28 Sleep patterns, physical activity and glycemic control in newly diagnosed type 2 diabetes patients from a joint perspective: a cross-sectional study Yuanquan Xu et al. 10.3389/fendo.2026.1845188 Frontiers in Endocrinology 2026 Scholar
29 CLINICS OF METABOLIC AND MORPHOMETRIC FACTORS ASSOCIATED WITH THE REMISSION OF TYPE 2 DIABETES AFTER BARIATRIC INTERVENTIONS B. Tavasharov 10.67519/nshr.ztj.2026.03.095 Journal of modern medicine 2026 Scholar
30 Polyethylene Glycol Loxenatide Selectively Reduces Adiposity While Preserving Lean Body Mass in Type 2 Diabetes: A 12-Week Clinical Study Rong Gu et al. 10.2147/DMSO.S592044 Diabetes, Metabolic Syndrome and Obesity 2026 Scholar
31 The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after three years of observation S. Maragkoudakis et al. 10.1093/ejhf/xuag193.1366 European Journal of Heart Failure 2026 Scholar
32 Analysis of Knowledge Level, Self-Efficacy, and Self-Management among Type 2 Diabetes Mellitus Patients in Rural Areas of Aceh Province Rihhadatul Aisy et al. 10.54543/kesans.v5i8.636 KESANS : International Journal of Health and Science 2026 Scholar
33 Exploratory Mediation-Informed Analysis and Dose–Response Analysis of Uric Acid Reduction and Kidney Outcomes in SGLT2 Inhibitor Therapy Compared to Allopurinol T. Jambor et al. 10.3390/medsci14040421 Medical Sciences 2026 Scholar
34 Diagnosis and risk factors in pancreatogenic diabetes. R. K. Sharma et al. 10.1016/bs.acc.2025.10.003 1 citation Advances in clinical chemistry 2026 Scholar
35 Somatostatin in Aging: Correlations with Selected Central Nervous System and Gastrointestinal Tract Diseases A. Kasprzak 10.3390/ijms27104244 International Journal of Molecular Sciences 2026 Scholar
36 Donepezil enhances the testicular protective effect of metformin in diabetic rats by modulating steroidogenic signaling and Bax/Bcl-2/Caspase-3 pathway. R. Akhigbe et al. 10.1016/j.steroids.2026.109748 Steroids 2026 Scholar
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Diabetes (Type 2)
  • Week: September 28 – October 5, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 16, 2026 at 6:57 AM
© 2026 DoctiPlus Care Vol. 7 · No. 47 · November 16, 2026 — 30 —